Shire news from FiercePharma
NewsShire recalls ADHD drug patches
Drug patches have had a tough time lately, with recalls coming on everything from too-tight adhesive to slits in active-ingredient reservoirs. Today, the recalled patch in the news is Shire's... Read more...
Is Shire worth a 25% premium?
Can Shire weather the upcoming loss of Adderall XR to the off-patent wildnerness? Company execs say it can: They point out that 60 percent of the company's revenues derive from other products. And... Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring... Read more...
Rumor Mill: AZ a possible Shire suitor
Shire is suddenly the talk of the town as investors and investment banks publicly mull a match-up with AstraZeneca. The U.K. drugmaker's stock gained 7 percent today after UBS said AstraZeneca could... Read more...
SPOTLIGHT: Investors expected to boost GSK, AZ
Credit Suisse lifted its share-price targets for GlaxoSmithKline, AstraZeneca, and Shire, saying it expects the pharma sector to be something of a port in a storm for investors worried about the... Read more...
Shire investor objects to CEO shift
One of Shire's shareholders is crying foul at the drug maker's big management reshuffling announced last... Read more...
Shire on lookout for acquisitions
Fresh off its best quarterly results ever, Shire says it's still in the market for smaller companies to buy. "That is how we get new products," CEO Matthew Emmens said. Shire's 41 percent... Read more...
ALSO NOTED: Korea fines pharma firms for kickbacks; Medco boosts profits 16 percent;
> Ten Korean drug makers were fined $22 million for illegal rebates to hospitals and wholesalers. Report >... Read more...
Shire casts off non-core drugs for $213M
UK-based Shire Pharmaceuticals is selling a block of medicines to Almirall of... Read more...
| Press ReleasesShire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA (mesalamine) and AsacolShire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA(R) (mesalamine) and Asacol(R) PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP; Read more >> PRESS RELEASE: Amicus Therapeutics, Inc. and Shire Pharmaceuticals Group Enter Into $440 Million ex-US Licensing Agreement Amicus Therapeutics and Shire Pharmaceuticals Group Enter Into $440 Million ex-US Licensing Agreement CRANBURY, N.J., Nov. 8 -- Amicus Therapeutics, Inc. announced today that it has entered into a Read more >> PRESS RELEASE: Shire Pharmaceuticals Group's Fosrenol Does Not Meet Main Goal of Trial Shire Pharmaceuticals Group's Fosrenol Does Not Meet Main Goal of Trial PHILADELPHIA and BASINGSTOKE, England, November 6 -- Shire plc today announced the results of a Phase II study indicating that Read more >> PRESS RELEASE: Shire Voluntarily Withdraws a Limited Portion of Daytrana (Methylphenidate Transdermal System) Patches Shire Voluntarily Withdraws a Limited Portion of Daytrana (Methylphenidate Transdermal System) Patches Patches that are easier to use are available for patients and their families PHILADELPHIA, Read more >> |
Get more Shire coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
